7 unchanged sentences
Our motion to dismiss was granted and the action was dismissed with prejudice by the District Court on August 14, 2020.
−Removed: The lead plaintiffs filed a notice of appeal to the U.S.
−Removed: Court of Appeals for the Fifth Circuit on September 11, 2020 and a brief in support of its appeal on December 17, 2020.
−Removed: We filed a response brief on February 18, 2021 and the lead plaintiffs filed a reply brief on March 11, 2021.
−Removed: Oral arguments were held on June 9, 2021.
−Removed: The lawsuit purports to be a class action brought on behalf of purchasers of our securities during the period from March 11, 2016 through July 29, 2019.
−Removed: The complaint alleges that the defendants violated federal securities laws by making materially false and misleading statements and/or omissions concerning data from our Phase 3 clinical trials of sotagliflozin in type 1 diabetes patients and the prospects of FDA approval of sotagliflozin for the treatment of type 1 diabetes.
−Removed: The complaint purports to assert claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
−Removed: The complaint seeks, on behalf of the purported class, an unspecified amount of monetary damages, interest, fees and expenses of attorneys and experts, and other relief.
+Added: The judgment of the District Court was affirmed by the U.S.
+Added: Court of Appeals for the Fifth Circuit on September 10, 2021.
+Added: The lawsuit purported to be a class action brought on behalf of purchasers of our securities during the period from March 11, 2016 through July 29, 2019.
+Added: The complaint alleged that the defendants violated federal securities laws by making materially false and misleading statements and/or omissions concerning data from our Phase 3 clinical trials of sotagliflozin in type 1 diabetes patients and the prospects of FDA approval of sotagliflozin for the treatment of type 1 diabetes.
+Added: The complaint purported to assert claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
+Added: The complaint sought, on behalf of the purported class, an unspecified amount of monetary damages, interest, fees and expenses of attorneys and experts, and other relief.
Sanofi Arbitration.
1 unchanged sentence
In September 2020, Sanofi withheld approximately $23.2 million from the final $26 million payment due to us under the termination and settlement agreement, offsetting certain third party costs and internal costs incurred by Sanofi and asserted by Sanofi to be payable by us under the terms of the termination and settlement agreement.
−Removed: We dispute that at least a significant portion of such costs are properly reimbursable by us under the terms of the termination and settlement agreement and assert that, in any event, Sanofi was not permitted to withhold any of such costs under the terms of the termination and settlement agreement.
−Removed: We are seeking payment of up to $23.2 million in such disputed costs, together with late interest and attorneys’ fees and costs.
−Removed: Sanofi is seeking a declaratory judgment that we are liable for all disputed costs previously withheld and damages for any additional costs properly reimbursable under the terms of the termination and settlement agreement in excess of those previously withheld, together with late interest and attorneys’ fees.
+Added: We disputed that at least a significant portion of such costs were properly reimbursable by us under the terms of the termination and settlement agreement and asserted that, in any event, Sanofi was not permitted to withhold any of such costs under the terms of the termination and settlement agreement.
+Added: We were seeking payment of $15.6 million in such disputed costs, together with late interest and attorneys’ fees and costs.
+Added: Sanofi was seeking a declaratory judgment that we are liable for all disputed costs previously withheld and damages for any additional costs properly reimbursable under the terms of the termination and settlement agreement in excess of those previously withheld, together with late interest and attorneys’ fees.
+Added: On November 5, 2021, the arbitration panel issued a judgment in Sanofi’s favor.
+Added: The amount of Sanofi’s attorneys’ fees and costs subject to reimbursement cannot be reasonably estimated at this time.
Normal Course Legal Proceedings.
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.